证券代码：600422 证券简称：昆药集团 公告编号：2024-066 号 召开地点：上证路演中心 昆药集团股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 昆药集团股份有限公司（以下简称"公司"）已于2024年10月26日发布公司2024年第三季 度报告，为便于广大投资者更全面深入地了解公司2024年第三季度经营成果、财务状况，公 司计划于2024年11月14日下午15:00-16:00举行2024年第三季度网上业绩说明会，就投资者关 心的问题进行交流。 一、 说明会类型 本次业绩说明会以网络互动方式召开，公司将针对2024年第三季度的经营成果及财务指 标等具体情况与投资者进行交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题 进行回答。 二、 说明会召开的时间、方式 召开时间：2024年11月14日（星期四）下午15:00-16:00。 召开方式：上证路演中心网络互动 三、 参加人员 公司副董事长兼总裁颜炜先生、财务总监孙志强先生、董事会秘书 ...

Investment Rating - The report maintains a "Recommended" rating for the company [1][4][10] Core Views - The company achieved a revenue of 54.57 billion yuan for the first three quarters of 2024, a decrease of 2.73% year-on-year, with a net profit attributable to shareholders of 3.87 billion yuan, an increase of 0.36% [3][4] - In Q3 2024, the company reported a revenue of 19.03 billion yuan, marking a 3.41% increase quarter-on-quarter, which is the first positive revenue growth quarter of 2024, indicating a positive trend [4][3] - The gross profit margin for the first three quarters of 2024 was 40.91%, down 4.15 percentage points, primarily due to changes in revenue structure [4] - The net profit margin was 7.16%, up 0.10 percentage points, mainly due to a significant improvement in the sales expense ratio, which was 25.99%, down 5.06 percentage points [4] Summary by Sections Financial Performance - The company’s revenue for Q3 2024 was 19.03 billion yuan, with a net profit of 1.58 billion yuan, a decrease of 2.91% [3] - The first three quarters of 2024 saw a gross profit margin of 40.91% and a net profit margin of 7.16% [4] Research and Development - R&D expenses increased by 39% to 60.01 million yuan in the first three quarters [4] - The company’s subsidiary received approval for a new drug, marking a significant milestone in its R&D efforts [4] Future Outlook - The company aims to achieve an industrial revenue target of 10 billion yuan by 2028, indicating a strong growth potential [4] - The report forecasts net profits of 5.52 billion yuan, 7.00 billion yuan, and 8.89 billion yuan for 2024, 2025, and 2026 respectively, with the current stock price corresponding to a P/E ratio of 20 times for 2024 [4][5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown a quarter-on-quarter increase in revenue and profit for Q3 2024, with a total revenue of 54.57 billion yuan for Q1-Q3 2024, reflecting a year-on-year decrease of 2.73%. The net profit attributable to the parent company was 3.87 billion yuan, up by 0.36% year-on-year [3] - The company is advancing its integration with China Resources Sanjiu, focusing on organizational innovation to enhance efficiency and drive new quality development [4] - The company is increasing its R&D investment, particularly in the fields of chronic disease management and aging health, with ongoing clinical trials for new drugs [5] Financial Performance Summary - For Q3 2024, the company achieved a revenue of 19.03 billion yuan, a year-on-year increase of 3.41%. The net profit attributable to the parent company was 1.58 billion yuan, down by 2.91% year-on-year [3] - The gross margin for Q1-Q3 2024 was 40.91%, a decrease of 4.15 percentage points, while the net margin was 7.16%, an increase of 0.09 percentage points [3] - The company forecasts net profits of 5.57 billion yuan, 7.04 billion yuan, and 8.51 billion yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 0.74 yuan, 0.93 yuan, and 1.12 yuan [3][6] Organizational and Strategic Developments - The company is implementing the "Leading Plan" to establish a new organizational structure that enhances strategic leadership, business empowerment, and value creation [4] - The focus on health aging and chronic disease management is expected to provide significant growth opportunities for the company [3][5] R&D and Product Development - The company is actively developing new drugs, including a Class I new drug for ischemic stroke currently in phase II clinical trials, and a Class II modified new drug entering clinical preparation [5]

公司点评报告 ·医药行业 责环比显著改善,聚焦银发健康产业 2024年三季报业绩点评 2024 年 10月 25 日 | --- | --- | --- | --- | |-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Total revenue for Q3 2024 reached ¥1,903,033,253.98, an increase of 3.41% year-over-year[2] - Net profit attributable to shareholders was ¥157,912,523.77, a decrease of 2.91% compared to the same period last year[2] - The net profit after deducting non-recurring gains and losses was ¥129,348,428.37, down 2.90% year-over-year[2] - Basic and diluted earnings per share were both ¥0.2086, reflecting a year-over-year increase of 1.36%[3] - Total operating revenue for the first three quarters of 2024 was CNY 5,457,454,882.94, a decrease of 2.72% compared to CNY 5,610,863,771.76 in the same period of 2023[15] - Net profit for the first three quarters of 2024 was CNY 390,513,080.86, compared to CNY 396,225,301.95 in the previous year, showing a decrease of 1.79%[17] - The net profit attributable to shareholders of the parent company for Q3 2024 is approximately CNY 387.40 million, compared to CNY 386.01 million in Q3 2023, reflecting a slight increase[18] - The total comprehensive income attributable to shareholders of the parent company for Q3 2024 is approximately CNY 386.48 million, up from CNY 384.92 million in Q3 2023[18] - The basic and diluted earnings per share for Q3 2024 are both CNY 0.5117, compared to CNY 0.5093 in Q3 2023[18] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥10,021,691,857.20, representing a 4.77% increase from the end of the previous year[3] - Total assets as of the end of Q3 2024 were CNY 10,021,691,857.20, up from CNY 9,565,383,273.17 at the end of Q3 2023, an increase of 4.78%[15] - Total liabilities increased to CNY 4,309,419,804.75 in Q3 2024 from CNY 4,088,813,874.21 in Q3 2023, reflecting a rise of 5.39%[15] - The total equity attributable to shareholders increased to CNY 5,532,501,840.76 in Q3 2024 from CNY 5,297,444,082.36 in Q3 2023, marking an increase of 4.43%[15] Cash Flow - The company reported a significant increase in cash flow from operating activities, with a net cash flow of ¥216,341,027.07, up 694.80% year-to-date[5] - Cash inflows from operating activities for the first three quarters of 2024 amount to approximately CNY 5.32 billion, down from CNY 5.64 billion in the same period of 2023, representing a decrease of about 5.6%[20] - The net cash flow from operating activities for the first three quarters of 2024 is CNY 216.34 million, a significant improvement from a net outflow of CNY 36.37 million in the same period of 2023[20] - Cash inflows from investment activities for the first three quarters of 2024 total approximately CNY 2.30 billion, compared to CNY 760.07 million in the same period of 2023, indicating a substantial increase[21] - The net cash flow from investment activities for the first three quarters of 2024 is negative CNY 104.72 million, an improvement from negative CNY 217.19 million in the same period of 2023[21] - Cash inflows from financing activities for the first three quarters of 2024 amount to approximately CNY 512.66 million, down from CNY 811.90 million in the same period of 2023[21] - The net cash flow from financing activities for the first three quarters of 2024 is negative CNY 272.77 million, compared to negative CNY 241.32 million in the same period of 2023[21] - The ending balance of cash and cash equivalents as of Q3 2024 is approximately CNY 1.20 billion, compared to CNY 1.06 billion at the end of Q3 2023[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 37,045[9] - The largest shareholder, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., holds 212,311,616 shares, accounting for 28.04% of total shares[9] - The total number of shares held by the top ten shareholders does not include any shares lent through margin trading[10] - There are no reported changes in the participation of major shareholders in margin trading or securities lending activities[10] Research and Development - The company is focusing on the elderly health sector and chronic disease management, with ongoing R&D efforts in traditional Chinese medicine and natural drugs[8] - Research and development expenses increased to CNY 60,014,539.23 in 2024 from CNY 43,325,919.08 in 2023, representing a growth of 38.38%[17] - The product "Colchicine Tablets" received approval from the National Medical Products Administration, marking a significant milestone in the company's product pipeline[8] Operational Efficiency - The new organizational structure aims to enhance operational efficiency and support strategic goals, fostering a customer-oriented approach[6] - The company completed the repurchase and cancellation of 138,240 restricted shares, reducing total shares from 757,113,997 to 756,975,757[11] - Accounts receivable increased to ¥3,089,748,102.01 from ¥2,550,997,985.02, reflecting a growth of about 21.06%[13] - Inventory decreased to ¥1,576,924,325.09 from ¥1,688,247,280.29, indicating a reduction of approximately 6.61%[13] - The total current assets as of September 30, 2024, are ¥7,554,757,129.88, up from ¥7,031,044,519.89, marking an increase of about 7.44%[13] - The company’s long-term equity investments decreased slightly from ¥23,790,872.85 to ¥23,500,304.62[13] - The company reported a decrease in sales expenses to CNY 1,418,514,480.00 in 2024 from CNY 1,742,085,743.45 in 2023, a reduction of 18.56%[17] - Deferred income tax assets rose to CNY 273,025,515.46 in Q3 2024 from CNY 262,616,900.75 in Q3 2023, an increase of 3.10%[15]

证券代码：600422 证券简称：昆药集团 公告编号：2024-063号 昆药集团股份有限公司十届二十八次监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昆药集团股份有限公司（以下简称"昆药集团"、"公司"）于 2024 年 10 月 25 日 以通讯表决方式召开公司十届二十八次监事会会议。会议通知以书面方式于 2024 年 10 月 15 日发出。会议由公司监事会主席钟江先生召集并主持，本次会议应参加表决 监事 5 人，实际参加表决 5 人，符合《公司法》和《公司章程》的规定。会议审议并 通过了以下决议： 1、 关于公司 2024 年第三季度报告的议案（公司 2024 年第三季度报告刊登于上海证 券交易所网站 www.sse.com） 同意：5 票 反对：0 票 弃权：0 票 监事会书面审核意见： 公司第三季度报告的编制和审议程序符合法律、法规、公司章程和公司内部管理 制度的各项规定；公司第三季度报告的内容和格式符合中国证监会和上海证券交易所 的各项规定，所包含的信息从各个方面真实地反映了公司第三季度的经营成 ...

证券代码：600422 证券简称：昆药集团 公告编号：2024-062号 昆药集团股份有限公司十届三十四次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昆药集团股份有限公司（以下简称"昆药集团"、"公司"）于 2024 年 10 月 25 日以 通讯表决方式召开公司十届三十四次董事会会议。会议通知以书面方式于 2024 年 10 月 15 日发出。会议由公司董事长邱华伟先生召集并主持，本次会议应参加表决董事 9 人，实际参加表决 9 人，符合《公司法》和《公司章程》的规定。会议以记名方式投 票表决，审议并通过以下决议： 1、 关于公司 2024 年第三季度报告的议案（公司 2024 年第三季度报告刊登于上海证 券交易所网站 www.sse.com.cn） 本议案已经公司十届董事会审计与风险控制委员会 2024 年第六次会议审议通过， 并同意提交公司董事会审议。 同意：9 票 反对：0 票 弃权：0 票 2、 关于公司部分人员薪酬相关事项的议案 根据公司业务发展需要，因部分管理人员聘任及工作调整，确定其薪酬相关 ...

重要内容提示： 昆药集团股份有限公司(以下简称"公司")本次会计政策变更是根据财政部相 关文件要求进行的合理变更，不会对公司财务状况、经营成果和现金流量产生重大影 响，不存在损害公司及股东利益的情况。 公司根据财政部修订并印发的企业会计准则的要求执行的会计政策变更，无 需公司董事会、监事会和股东大会审议。 一、本次会计政策变更概述 证券代码：600422 证券简称：昆药集团 公告编号：2024-064号 昆药集团股份有限公司 关于公司会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （一）本次会计政策变更原因 2023 年 8 月，财政部发布了《关于印发<企业数据资源相关会计处理暂行规定> 的通知》（财会〔2023〕11 号）（以下简称"《数据资源暂行规定》"），规定了"企 业数据资源相关会计处理"的内容，自 2024 年 1 月 1 日起施行。 2023 年 10 月，财政部发布了《企业会计准则解释第 17 号》（财会〔2023〕21 号）（以下简称"《准则解释第 17 号》"），对"关于流动负债与非流动负 ...

重要内容提示： 证券代码：600422 证券简称：昆药集团 公告编号：2024-061号 昆药集团股份有限公司关于对外担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 担保情况概述 （1）担保事项履行的相关程序 为支持昆药集团股份有限公司（以下简称"公司"）旗下全资及控股子公司 2024 年 生产经营及业务发展需要，满足相关下属公司融资担保需求，经公司十届二十三次董 事会及 2024 年第三次临时股东大会审议通过，2024 年度由公司及下属子公司为旗下 公司合计不超过人民币 6.06 亿元的银行融资授信业务提供连带责任担保，详见《昆药 集团股份有限公司关于 2024 年度担保计划的公告》（2024-015 号）和《昆药集团股 份有限公司 2024 年第三次临时股东大会决议公告》（2024-028 号）。 （2）担保概况 为支持旗下全资及控股子公司生产经营及业务发展，2024 年 10 月 22 日，在上述 批准范围内公司发生如下担保（单位：万元）： 1 被担保人：曲靖市康桥医药有限责任公司（以下简称"曲靖康 ...

证券代码：600422 证券简称：昆药集团 公告编号：2024-060 昆药集团股份有限公司 2024 年第五次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2024 年 10 月 15 日 (二)股东大会召开的地点：云南省昆明市国家高新技术开发区科医路 166 号昆药 集团股份有限公司管理中心 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 599 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 353,926,269 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 46.7552 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 审议结果：通过 表决情况： | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | ...